+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNac Conjugates Market - Global Forecast 2025-2030- Product Image
GalNac Conjugates Market - Global Forecast 2025-2030- Product Image
Sale

GalNac Conjugates Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6133698
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

GalNAc conjugates are redefining the precision medicine landscape by advancing targeted delivery of oligonucleotide therapies directly to liver cells. By leveraging this technology, biopharmaceutical organizations improve therapeutic precision and operational efficiency while mitigating systemic exposure. Senior decision-makers evaluating next-generation interventions will find actionable intelligence in this comprehensive analysis of the global GalNAc conjugate market.

Market Snapshot: GalNAc Conjugates Market Overview

The GalNAc conjugates market has become central to the evolution of RNA-based therapeutics. Marked by increasing clinical advancements, regulatory approvals, and strategic investments, the sector is attracting biopharma leaders seeking differentiated delivery solutions. Established players and innovative biotech firms are rapidly expanding GalNAc-enabled portfolios, driven by robust R&D pipelines and sustained demand for precise hepatic therapies. Regional dynamics are influenced by regulatory alignment, advanced manufacturing ecosystems, and ongoing strategic collaborations, creating persistent growth opportunities for stakeholders prioritizing targeted liver disease interventions.

Scope & Segmentation of the GalNAc Conjugates Market

  • Therapeutic Areas: Hepatic disorders (including nonalcoholic fatty liver disease, viral hepatitis); metabolic disorders (hypercholesterolemia, NASH); oncology (liver cancer); rare genetic diseases (hemophilia, spinal muscular atrophy).
  • Indications: Hemophilia, hypercholesterolemia, liver cancer, NASH, spinal muscular atrophy, viral hepatitis.
  • Molecule Types: Antisense oligonucleotide conjugates, microRNA conjugates, siRNA conjugates.
  • Administration Routes: Intravenous, subcutaneous.
  • End Users: Hospitals, research institutes, specialty clinics.
  • Geographic Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Alnylam Pharmaceuticals, Novartis AG, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Roche Holding, Dicerna Pharmaceuticals, Akcea Therapeutics, Moderna, GlycoMimetics.

Key Takeaways for Decision-Makers

  • GalNAc conjugation has enabled significant clinical breakthroughs in liver disease treatment by improving drug delivery specificity via the asialoglycoprotein receptor pathway.
  • Strategic alliances between biotechnology firms, CDMOs, and academic centers have accelerated innovation, providing enhanced access to novel targets and expertise.
  • Recent regulatory streamlining is supporting faster development and earlier clinical validation for GalNAc-based therapeutics, facilitating swifter market entry.
  • Process improvements in ligand design, oligonucleotide stability, and GMP manufacturing are directly elevating pharmacokinetic profiles and reducing immunogenicity, improving product viability and patient outcomes.
  • Expanding the application of GalNAc ligands to non-hepatic indications is under exploration, signaling future diversification opportunities for biopharma R&D investment.
  • Clinical pipeline diversity is informing indication-tailored strategies and customized endpoints, underscoring the need for adaptive development frameworks in a competitive landscape.

Tariff Impact: Navigating Supply Chain and Cost Management

New U.S. tariffs effective in 2025 are imposing higher costs on critical raw materials such as carbohydrate linkers and nucleotide building blocks, affecting the GalNAc conjugates supply chain. Manufacturers are responding by diversifying sourcing strategies, exploring tariff-exempt suppliers, and investing in domestic capabilities. These cost pressures are prompting recalibration of service agreements within CROs and payer negotiations. Organizations are adopting dual-sourcing, integrating tariff forecasting, and advocating for modifications to safeguard production resilience and maintain therapeutic viability in an evolving trade environment.

Methodology & Data Sources

Our research employs structured interviews with senior industry stakeholders, triangulated with company filings, patent databases, and clinical trial registries. Systematic secondary review covers peer-reviewed literature, regulator reports, and proprietary databases, ensuring analytical rigor. All data points are validated through multi-source cross-referencing and expert panel review.

Why This Report Matters to Senior Executives

  • Enables benchmarking of organizational strategy against current innovation and regulatory momentum in the GalNAc conjugates market.
  • Informs purchasing, supply chain, and investment decisions amidst emerging geopolitical and tariff-related challenges.
  • Supports R&D and commercial planning by highlighting actionable clinical and operational insights across major regions and technology segments.

Conclusion

GalNAc conjugates are reshaping the delivery of oligonucleotide therapies and raising the benchmark for targeted liver-directed treatments. Industry leaders who proactively adapt to evolving technology, regulatory, and trade landscapes will unlock new therapeutic potential and sustained market growth.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expanded use of GalNAc-siRNA conjugates for chronic liver disease therapies including NASH and fibrosis
5.2. Advances in multivalent GalNAc conjugation strategies improving endosomal escape efficiency
5.3. Growing pipeline of GalNAc-ASO therapeutics targeting non-liver tissues through receptor modifications
5.4. Innovations in next-generation GalNAc conjugate formulations enhancing stability and bioavailability
5.5. Strategic collaborations between biotech firms and CROs to accelerate GalNAc drug candidates into clinical trials
5.6. Regulatory feedback shaping clinical development pathways for GalNAc-based nucleic acid therapies
5.7. Scale-up manufacturing improvements reducing production costs for GalNAc conjugate oligonucleotides
5.8. Emerging linker chemistries enabling controlled release of GalNAc-conjugated nucleic acids in hepatocytes
5.9. Clinical safety profiling of GalNAc therapeutics focusing on immunogenicity and off-target effects
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. GalNac Conjugates Market, by Therapeutic Area
8.1. Introduction
8.2. Hepatic Disorders
8.2.1. Nonalcoholic Fatty Liver Disease
8.2.2. Viral Hepatitis
8.3. Metabolic Disorders
8.3.1. Hypercholesterolemia
8.3.2. Nash
8.4. Oncology
8.4.1. Liver Cancer
8.5. Rare Genetic Diseases
8.5.1. Hemophilia
8.5.2. Spinal Muscular Atrophy
9. GalNac Conjugates Market, by Indication
9.1. Introduction
9.2. Hemophilia
9.3. Hypercholesterolemia
9.4. Liver Cancer
9.5. Nash
9.6. Spinal Muscular Atrophy
9.7. Viral Hepatitis
10. GalNac Conjugates Market, by Molecule Type
10.1. Introduction
10.2. Antisense Oligonucleotide Conjugates
10.3. Microrna Conjugates
10.4. Sirna Conjugates
11. GalNac Conjugates Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.3. Subcutaneous
12. GalNac Conjugates Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Research Institutes
12.4. Specialty Clinics
13. Americas GalNac Conjugates Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa GalNac Conjugates Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific GalNac Conjugates Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals, Inc.
16.3.2. Novartis AG
16.3.3. Ionis Pharmaceuticals, Inc.
16.3.4. Arrowhead Pharmaceuticals, Inc.
16.3.5. Silence Therapeutics plc
16.3.6. Roche Holding AG
16.3.7. Dicerna Pharmaceuticals, Inc.
16.3.8. Akcea Therapeutics, Inc.
16.3.9. Moderna, Inc.
16.3.10. GlycoMimetics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GALNAC CONJUGATES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GALNAC CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GALNAC CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GALNAC CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GALNAC CONJUGATES MARKET: RESEARCHAI
FIGURE 26. GALNAC CONJUGATES MARKET: RESEARCHSTATISTICS
FIGURE 27. GALNAC CONJUGATES MARKET: RESEARCHCONTACTS
FIGURE 28. GALNAC CONJUGATES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GALNAC CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GALNAC CONJUGATES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GALNAC CONJUGATES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NONALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NONALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NASH, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NASH, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NASH, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY NASH, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY VIRAL HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MICRORNA CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY MICRORNA CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SIRNA CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SIRNA CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GALNAC CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES GALNAC CONJUGATES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 117. CANADA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 118. CANADA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 119. CANADA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 120. CANADA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 121. CANADA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 122. CANADA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 123. CANADA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 124. CANADA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 125. CANADA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 126. CANADA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 127. CANADA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 132. CANADA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 133. CANADA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. CANADA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. MEXICO GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 136. MEXICO GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 137. MEXICO GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 143. MEXICO GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 144. MEXICO GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 150. MEXICO GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 151. MEXICO GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. MEXICO GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA GALNAC CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. GERMANY GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 228. GERMANY GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 229. GERMANY GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 234. GERMANY GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 235. GERMANY GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 236. GERMANY GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 240. GERMANY GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 241. GERMANY GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 242. GERMANY GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 243. GERMANY GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. GERMANY GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. FRANCE GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 246. FRANCE GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 247. FRANCE GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 252. FRANCE GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 253. FRANCE GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 254. FRANCE GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 258. FRANCE GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 259. FRANCE GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 260. FRANCE GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 261. FRANCE GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. FRANCE GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. ITALY GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 282. ITALY GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 283. ITALY GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 284. ITALY GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 285. ITALY GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 286. ITALY GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 287. ITALY GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 288. ITALY GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 289. ITALY GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 290. ITALY GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 291. ITALY GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 294. ITALY GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 295. ITALY GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 296. ITALY GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 297. ITALY GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. ITALY GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. SPAIN GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 300. SPAIN GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 301. SPAIN GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 306. SPAIN GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 307. SPAIN GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 308. SPAIN GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. SPAIN GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 312. SPAIN GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 313. SPAIN GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 314. SPAIN GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 315. SPAIN GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SPAIN GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 332. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 333. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. UNITED ARAB EMIRATES GALNAC CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA GALNAC CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA GALNAC CONJUGATES MARKET SIZE, BY HEPATIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA GALNAC CON

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this GalNac Conjugates market report include:
  • Alnylam Pharmaceuticals, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Roche Holding AG
  • Dicerna Pharmaceuticals, Inc.
  • Akcea Therapeutics, Inc.
  • Moderna, Inc.
  • GlycoMimetics, Inc.

Related Reports

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2025-2030 - Product Image

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

SiRNA Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • 204 Pages
  • Global
From
RNAi Technology - Global Strategic Business Report - Product Image

RNAi Technology - Global Strategic Business Report

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.